Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis

医学 华法林 内科学 达比加群 肾脏疾病 药物治疗 荟萃分析 透析 重症监护医学 心房颤动
作者
Hsin-Yu Chen,Shih-Hsiang Ou,Chien‐Wei Huang,Po‐Tsang Lee,Kang-Ju Chou,Pei‐Chin Lin,Yi‐Chia Su
出处
期刊:Clinical Drug Investigation [Adis, Springer Healthcare]
卷期号:41 (4): 341-351 被引量:26
标识
DOI:10.1007/s40261-021-01016-7
摘要

Systematic reviews and meta-analyses of direct oral anticoagulants (DOACs) for patients with chronic kidney disease (CKD) or dialysis patients are lacking. We aimed to compare the efficacy and safety of DOACs and warfarin in patients with CKD requiring anticoagulation therapy. We performed a systematic review and meta-analysis of six randomized controlled trials and 19 observational studies, with the inclusion criteria being a comparative study between DOACs and warfarin in patients with CKD or dialysis patients from database inception until August 2020. The efficacy outcomes were stroke, systemic embolism (SE), or venous thromboembolism (VTE), and the safety outcome was major bleeding. Compared with warfarin, DOACs significantly reduced the risk of stroke/SE/VTE by 22% (hazard ratio [HR] = 0.78, 95% confidence interval [CI] 0.64–0.95) and major bleeding by 17% (HR = 0.83, 95% CI 0.71–0.97). On comparing factor Xa inhibitors and dabigatran with warfarin separately, factor Xa inhibitors significantly reduced the risk of stroke/SE/VTE (HR = 0.78, 95% CI 0.62–0.98) and major bleeding (HR = 0.76, 95% CI 0.64–0.91) overall in patients. Comparing each DOACs with warfarin separately, apixaban was associated with a significantly better risk reduction of stroke/SE/VTE (25% risk reduction) and major bleeding (35% risk reduction) than warfarin. Compared with warfarin, DOACs significantly reduced the risk of stroke, SE, or VTE by 19% (HR = 0.81, 95% CI 0.68–0.97) in patients with CKD stage 3 and significantly lowered the risk of major bleeding by 31% (HR = 0.69, 95% CI 0.56–0.85) in patients with CKD stages 4–5. In pooled, analyzed randomized controlled trials and observational studies, DOACs were associated with better efficacy in early CKD, as well as similar efficacy and safety outcomes to warfarin in patients with CKD stages 4–5 or dialysis patients. The results of patients with CKD stages 4–5 and dialysis patients were from observational studies. Well-designed randomized controlled trials focused on DOAC use in patients with CKD and dialysis patients are needed. PROSPERO register number: CRD42020150599, 6 February, 2020.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
清新完成签到,获得积分10
刚刚
罗杰发布了新的文献求助10
刚刚
1秒前
2秒前
2秒前
情怀的应助被好运气都来采纳,获得30
2秒前
2秒前
追寻飞绿发布了新的文献求助10
2秒前
bkagyin的应助被拼搏的雨寒采纳,获得10
2秒前
YK完成签到,获得积分10
3秒前
yly发布了新的文献求助10
3秒前
猪皮king发布了新的文献求助50
3秒前
3秒前
HZW完成签到 ,获得积分10
3秒前
3秒前
XXXXX发布了新的文献求助10
4秒前
搜集达人的应助被kk采纳,获得10
4秒前
玉米侠完成签到,获得积分10
4秒前
4秒前
罗杰发布了新的文献求助10
4秒前
万能图书馆的应助被xiaoxiao采纳,获得10
4秒前
4秒前
doublenine18发布了新的文献求助10
4秒前
heoouijee完成签到,获得积分10
4秒前
4秒前
儒雅的风华完成签到,获得积分10
4秒前
melaniepollard完成签到,获得积分10
5秒前
5秒前
ggf发布了新的文献求助10
5秒前
nuo发布了新的文献求助10
5秒前
5秒前
6秒前
Hello的应助被体贴夏柳采纳,获得10
6秒前
gao发布了新的文献求助10
6秒前
hututu发布了新的文献求助20
6秒前
罗杰发布了新的文献求助10
6秒前
kaka完成签到,获得积分10
7秒前
shmily完成签到,获得积分20
7秒前
罗杰发布了新的文献求助10
7秒前
斯文败类的应助被penny采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8157019
求助须知:如何正确求助?哪些是违规求助? 9553131
关于积分的说明 21713003
捐赠科研通 7746165
什么是DOI,文献DOI怎么找? 3426705
关于科研通互助平台的介绍 2551467
邀请新用户注册赠送积分活动 2470603